questionsmedicales.fr
Maladies endocriniennes
Maladies de la parathyroïde
Hyperparathyroïdie
Hyperparathyroïdie : Questions médicales fréquentes
Diagnostic
5
Hyperparathyroïdie
Calcium
Hormone parathyroïdienne
Échographie
Scintigraphie
Hyperparathyroïdie
Hypercalcémie
Hormone parathyroïdienne
Hyperparathyroïdie
Symptômes
Calculs rénaux
Hyperparathyroïdie
Biopsie
Hyperparathyroïdie
Pathologie
Symptômes
5
Fatigue
Douleurs osseuses
Hyperparathyroïdie
Calculs rénaux
Hypercalcémie
Hyperparathyroïdie
Troubles de l'humeur
Anxiété
Hyperparathyroïdie
Déminéralisation osseuse
Fractures
Hyperparathyroïdie
Nausées
Constipation
Hyperparathyroïdie
Prévention
5
Prévention
Suivi médical
Hyperparathyroïdie
Alimentation
Calcium
Hyperparathyroïdie
Antécédents familiaux
Facteurs de risque
Hyperparathyroïdie
Dépistage
Symptômes
Hyperparathyroïdie
Mode de vie
Exercice
Hyperparathyroïdie
Traitements
5
Chirurgie
Médicaments
Hyperparathyroïdie
Chirurgie
Hyperparathyroïdie primaire
Symptômes
Bisphosphonates
Calcimimétiques
Hyperparathyroïdie
Surveillance
Calcium
Hormone parathyroïdienne
Traitements médicamenteux
Symptômes
Hyperparathyroïdie
Complications
5
Ostéoporose
Calculs rénaux
Maladies cardiovasculaires
Lésions rénales
Hypercalcémie
Hyperparathyroïdie
Fractures
Déminéralisation osseuse
Hyperparathyroïdie
Problèmes cardiovasculaires
Hypercalcémie
Hyperparathyroïdie
Troubles neurologiques
Confusion
Hyperparathyroïdie
Facteurs de risque
5
Âge avancé
Sexe féminin
Antécédents familiaux
Syndrome de MEN
Maladies endocriniennes
Hyperparathyroïdie
Lithium
Traitement
Hyperparathyroïdie
Hypercalcémie
Facteurs de risque
Hyperparathyroïdie
Mode de vie
Alimentation
Hyperparathyroïdie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperparathyroïdie : Questions médicales les plus fréquentes",
"headline": "Hyperparathyroïdie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperparathyroïdie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-05",
"dateModified": "2026-01-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperparathyroïdie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maladies de la parathyroïde",
"url": "https://questionsmedicales.fr/mesh/D010279",
"about": {
"@type": "MedicalCondition",
"name": "Maladies de la parathyroïde",
"code": {
"@type": "MedicalCode",
"code": "D010279",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.642"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hyperparathyroïdie primitive",
"alternateName": "Hyperparathyroidism, Primary",
"url": "https://questionsmedicales.fr/mesh/D049950",
"about": {
"@type": "MedicalCondition",
"name": "Hyperparathyroïdie primitive",
"code": {
"@type": "MedicalCode",
"code": "D049950",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.642.355.239"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hyperparathyroïdie secondaire",
"alternateName": "Hyperparathyroidism, Secondary",
"url": "https://questionsmedicales.fr/mesh/D006962",
"about": {
"@type": "MedicalCondition",
"name": "Hyperparathyroïdie secondaire",
"code": {
"@type": "MedicalCode",
"code": "D006962",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.642.355.480"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperparathyroïdie",
"alternateName": "Hyperparathyroidism",
"code": {
"@type": "MedicalCode",
"code": "D006961",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Natalie E Cusano",
"url": "https://questionsmedicales.fr/author/Natalie%20E%20Cusano",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology, Lenox Hill Hospital, New York, NY, USA."
}
},
{
"@type": "Person",
"name": "Carolina A Moreira",
"url": "https://questionsmedicales.fr/author/Carolina%20A%20Moreira",
"affiliation": {
"@type": "Organization",
"name": "Serviço de Endocrinologia e Metabologia do Hospital de Clínicas da Universidade Federal do Paraná (SEMPR), Curitiba, Brazil; Lab Pro, Bone Histomorphometry, Fundação Pro Renal, Curitiba, Brazil. Electronic address: carolina.aguiar.moreira@gmail.com."
}
},
{
"@type": "Person",
"name": "John P Bilezikian",
"url": "https://questionsmedicales.fr/author/John%20P%20Bilezikian",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: jpb2@columbia.edu."
}
},
{
"@type": "Person",
"name": "Piergiorgio Messa",
"url": "https://questionsmedicales.fr/author/Piergiorgio%20Messa",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Simon Mifsud",
"url": "https://questionsmedicales.fr/author/Simon%20Mifsud",
"affiliation": {
"@type": "Organization",
"name": "Department of Diabetes and Endocrinology, Mater Dei Hospital, Msida, Malta."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Surgery for Normocalcemic Hyperparathyroidism.",
"datePublished": "2023-08-25",
"url": "https://questionsmedicales.fr/article/37634986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.otc.2023.07.012"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetics of hereditary forms of primary hyperparathyroidism.",
"datePublished": "2023-12-01",
"url": "https://questionsmedicales.fr/article/38038882",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s42000-023-00508-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Persistent hyperparathyroidism after preemptive kidney transplantation.",
"datePublished": "2023-06-23",
"url": "https://questionsmedicales.fr/article/37351681",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10157-023-02371-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Missed Opportunities to Diagnose and Treat Tertiary Hyperparathyroidism After Transplant.",
"datePublished": "2023-02-27",
"url": "https://questionsmedicales.fr/article/36857809",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2023.01.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Does race impact outcomes after parathyroidectomy for secondary and tertiary hyperparathyroidism?",
"datePublished": "2023-07-11",
"url": "https://questionsmedicales.fr/article/37453804",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amjsurg.2023.07.013"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la parathyroïde",
"item": "https://questionsmedicales.fr/mesh/D010279"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hyperparathyroïdie",
"item": "https://questionsmedicales.fr/mesh/D006961"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperparathyroïdie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperparathyroïdie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperparathyroïdie",
"description": "Comment diagnostiquer l'hyperparathyroïdie ?\nQuels tests d'imagerie sont utilisés ?\nQuels sont les signes biologiques ?\nQuand suspecter une hyperparathyroïdie ?\nQuel rôle joue la biopsie ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperparathyroïdie",
"description": "Quels sont les symptômes courants ?\nL'hyperparathyroïdie cause-t-elle des calculs rénaux ?\nY a-t-il des effets sur l'humeur ?\nComment l'hyperparathyroïdie affecte-t-elle les os ?\nPeut-elle causer des problèmes digestifs ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperparathyroïdie",
"description": "Peut-on prévenir l'hyperparathyroïdie ?\nQuel rôle joue l'alimentation ?\nLes antécédents familiaux sont-ils un facteur ?\nComment le dépistage aide-t-il ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperparathyroïdie",
"description": "Quels sont les traitements disponibles ?\nQuand la chirurgie est-elle nécessaire ?\nQuels médicaments sont utilisés ?\nComment se déroule la surveillance ?\nY a-t-il des traitements non chirurgicaux ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperparathyroïdie",
"description": "Quelles complications peuvent survenir ?\nL'hyperparathyroïdie affecte-t-elle les reins ?\nY a-t-il un risque accru de fractures ?\nComment l'hyperparathyroïdie affecte-t-elle le cœur ?\nDes troubles neurologiques sont-ils possibles ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperparathyroïdie",
"description": "Quels sont les principaux facteurs de risque ?\nLes maladies endocriniennes augmentent-elles le risque ?\nLe traitement par lithium est-il un facteur ?\nL'hypercalcémie est-elle un facteur de risque ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006961#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperparathyroïdie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines mesurant le calcium et la PTH."
}
},
{
"@type": "Question",
"name": "Quels tests d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les échographies et les scintigraphies peuvent aider à localiser les glandes parathyroïdes."
}
},
{
"@type": "Question",
"name": "Quels sont les signes biologiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hypercalcémie et une élévation de la PTH sont des signes clés du diagnostic."
}
},
{
"@type": "Question",
"name": "Quand suspecter une hyperparathyroïdie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de symptômes comme des douleurs osseuses ou des calculs rénaux, suspectez-la."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie est rarement nécessaire, mais peut être utilisée pour exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, douleurs osseuses, et troubles digestifs."
}
},
{
"@type": "Question",
"name": "L'hyperparathyroïdie cause-t-elle des calculs rénaux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'excès de calcium peut entraîner la formation de calculs rénaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur l'humeur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de l'humeur comme l'anxiété peuvent survenir en raison de déséquilibres chimiques."
}
},
{
"@type": "Question",
"name": "Comment l'hyperparathyroïdie affecte-t-elle les os ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une déminéralisation osseuse, augmentant le risque de fractures."
}
},
{
"@type": "Question",
"name": "Peut-elle causer des problèmes digestifs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements et constipation sont fréquents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hyperparathyroïdie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais un suivi médical régulier aide."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut aider à maintenir des niveaux de calcium appropriés."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hyperparathyroïdie augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment le dépistage aide-t-il ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet de détecter la maladie avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant exercice et nutrition, peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, les médicaments et la surveillance régulière."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est indiquée en cas d'hyperparathyroïdie primaire symptomatique."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des bisphosphonates et des calcimimétiques peuvent être prescrits pour gérer la condition."
}
},
{
"@type": "Question",
"name": "Comment se déroule la surveillance ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance implique des contrôles réguliers des niveaux de calcium et de PTH."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non chirurgicaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements médicamenteux peuvent aider à gérer les symptômes sans chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'ostéoporose, les calculs rénaux et les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hyperparathyroïdie affecte-t-elle les reins ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des lésions rénales dues à une hypercalcémie prolongée."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de fractures ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déminéralisation osseuse augmente le risque de fractures osseuses."
}
},
{
"@type": "Question",
"name": "Comment l'hyperparathyroïdie affecte-t-elle le cœur ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut contribuer à des problèmes cardiovasculaires en raison de l'hypercalcémie."
}
},
{
"@type": "Question",
"name": "Des troubles neurologiques sont-ils possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques comme la confusion peuvent survenir dans les cas graves."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, le sexe féminin et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les maladies endocriniennes augmentent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le syndrome de MEN peuvent augmenter le risque d'hyperparathyroïdie."
}
},
{
"@type": "Question",
"name": "Le traitement par lithium est-il un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lithium peut être associé à un risque accru d'hyperparathyroïdie."
}
},
{
"@type": "Question",
"name": "L'hypercalcémie est-elle un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hypercalcémie chronique peut être un indicateur de risque pour l'hyperparathyroïdie."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/01/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Division of Endocrinology, Lenox Hill Hospital, New York, NY, USA.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Serviço de Endocrinologia e Metabologia do Hospital de Clínicas da Universidade Federal do Paraná (SEMPR), Curitiba, Brazil; Lab Pro, Bone Histomorphometry, Fundação Pro Renal, Curitiba, Brazil. Electronic address: carolina.aguiar.moreira@gmail.com.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: jpb2@columbia.edu.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Diabetes and Endocrinology, Mater Dei Hospital, Msida, Malta.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Mater Dei Hospital, Msida, Malta.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Diabetes and Endocrinology, Mater Dei Hospital, Msida, Malta.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Endocrine Unit, University Hospital of Pisa, Pisa, Italy, cetani@endoc.med.unipi.it.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Division of Endocrinology, University of Pernambuco Medical School Recife, Recife, Brazil.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Experimental Medicine, University of Pisa, Endocrine Unit 2, University Hospital of Pisa, Pisa, Italy.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Sciences Lund, Department of Surgery Section of Endocrine and Sarcoma Lund, Skåne University Hospital, Lund University, Lund, Sweden.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, Rome 00161, Italy. Electronic address: cristiana.cipriani@gmail.com.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
University of Alabama at Birmingham, Birmingham, AL 35233.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
University of Alabama at Birmingham, Birmingham, AL 35233.
Publications dans "Hyperparathyroïdie" :
2 publications dans cette catégorie
Affiliations :
Klinik für Viszeral‑, Gefäß- und Endokrine Chirurgie, Universitätsklinikum Halle, Martin-Luther Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle an der Saale, Deutschland. kerstin.lorenz@uk-halle.de.
Publications dans "Hyperparathyroïdie" :
Primary hyperparathyroidism is the most common cause of hypercalcemia, accounting for about 90% of all cases. This disorder is characterized by overactive parathyroid glands, leading to increased para...
Primary hyperparathyroidism (PHPT), a relatively common disorder characterized by hypercalcemia with raised or inappropriately normal serum parathyroid hormone (PTH) concentrations, may occur as part ...
Long-term dialysis vintage is a predictor of persistent hyperparathyroidism (HPT) after kidney transplantation (KTx). Recently, preemptive kidney transplantation (PKT) has increased. However, the inci...
In this retrospective cohort study, we enrolled patients who underwent PKT between 2000 and 2016. Those who lost their graft within 1 year posttransplant were excluded. HPT was defined as an intact pa...
Among the 340 consecutive patients who underwent PKT, 188 did not have HPT (HPT-free group) and 152 had HPT (HPT group). Multivariate logistic regression analysis revealed that pretransplant PTH level...
Pretransplant PTH levels and donor kidney function were independent predictors of HPT after PKT. In addition, HPT was associated with worse graft outcomes even after PKT....
Tertiary hyperparathyroidism (3HPT) is common after renal transplant. However, guidelines for diagnosis are not clear and few patients are treated surgically. This study aims to determine rates of dia...
This retrospective chart review identified all renal transplant recipients at a single tertiary care institution between 2011 and 2021. Patients with post-transplant hypercalcemia (> 10.2 mg/dL) were ...
Of 383 renal transplant recipients, hypercalcemia was identified in 132 patients. The majority of hypercalcemic patients had PTH levels measured (127, 96.2%). PTH was elevated in 109 (82.6%). Among th...
3HPT is underdiagnosed in patients with elevated calcium and PTH levels post-transplant. A significant percentage of these patients go without surgical referral and curative treatment....
Racial disparities in care exist for diseases with heterogeneous treatment guidelines. The impact of these disparities on outcomes after parathyroidectomy for secondary(2HPT) and tertiary hyperparathy...
The 2015-2019 NSQIP datasets were used. Patients who underwent parathyroidectomy for 2HPT and 3HPT were identified and analyzed separately. Patients were stratified by race (white vs. non-white); demo...
There were 1,150 patients with 2HPT and 262 with 3HPT. For 2HPT, 65.5% were non-white; morbidity, reoperation, and prolonged LOS(>3days) occurred disproportionately more often in non-white patients. N...
Race and markers of advanced disease negatively impact outcomes after parathyroidectomy for 2HPT and 3HPT. Attention to racial disparities and earlier referral may positively impact outcomes....
We retrospectively evaluated how accurately preoperative imaging localizes parathyroid adenoma in superior versus inferior parathyroids. Over 6 years, 104 patients with primary hyperparathyroidism und...
Tertiary hyperparathyroidism (THPT) is a peculiar subtype of hyperparathyroidism that usually develops from chronic kidney disease (CKD) and persists even after kidney transplantation. Unlike its prec...
In this study, we analyzed DNA samples from hyperplastic parathyroid and corresponding blood cells of 11 patients with THPT using whole-exome sequencing (WES). We identified somatic single nucleotide ...
Following quality control and mutation filtering, we identified 17,401 mutations, comprising 6690 missense variants, 3078 frameshift variants, 2005 stop-gained variants, and 1630 synonymous variants. ...
This study provides a comprehensive landscape of the genetic characteristics of hyperplastic parathyroids in THPT, highlighting the involvement of multiple genes and pathways in the development and pr...
In severe renal hyperparathyroidism (RHPT), whether administrating Cinacalcet before total parathyroidectomy can reduce post-operative hypocalcemia remains unclear. We compared post-operative calcium ...
Patients with severe RHPT (defined by PTH ≥ 100 pmol/L) who underwent total parathyroidectomy between 2012 and 2022 were analyzed. Standardized peri-operative protocol of calcium and vitamin D supplem...
Among 159 patients who underwent parathyroidectomy, 82 patients were eligible for analysis (Group I, n = 27; Group II, n = 55). Demographics and PTH levels before Cinacalcet administration were compar...
In severe RHPT, Cinacalcet led to significant drop in pre-operative PTH, higher post-operative calcium levels, and less frequent severe hypocalcemia. Longer duration of Cinacalcet use correlated with ...
Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture; however, the mechanism is unclear. PPI users taking calcium supplements were more likely to have hyperparathy...
Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture. Hyperparathyroidism may be implicated, but few studies have considered this relationship. This study evaluate...
Participants were from the TUDA study, a large cross-sectional cohort of older Irish adults. Participants with an estimated glomerular filtration rate (eGFR) < 30 ml/min and serum calcium > 2.5 mmol/l...
A total of 4139 participants met the inclusion criteria, of whom 37.8% (n = 1563) were taking PPI medication. PPI use was identified in 41.4% of calcium supplement users and 35.4% of non-calcium suppl...
The results are consistent with the hypothesis of PPIs reducing calcium absorption, leading to a rise in PTH which could mediate increased fracture risk. No relationship of PPI use with hyperparathyro...
Tertiary hyperparathyroidism (THPT) is characterized by elevated parathyroid hormone and serum calcium levels after kidney transplantation (KTx). To ascertain whether pre-transplant calcimimetic use a...